MedCity News April 19, 2021
Antibody therapies are seen as one way to overcome the variants that continue to fuel the pandemic. With its Series C financing, Adagio Therapeutics, led by CEO Tillman Gerngross, will proceed with a pivotal clinical trial of an antibody that has neutralized SARS-CoV-2 variants in lab and animal tests.
Adagio Therapeutics, a biotech developing antibody therapies that could potentially address the variants the continue to drive the spread of the novel coronavirus, has raised $336 million to conduct a pivotal study of its lead experimental treatment.
The new capital, a Series C round of funding, was led by RA Capital Management. It comes nine months after Waltham, Massachusetts-based Adagio launched with science from Adimab, a company that discovers and engineers...
Today's Sponsors
Today's Sponsor